438564-37-5

Usage

Uses

Used in Chemical Research and Development:
3,4-Diamino-6-trifluoromethylpyridine is used as a structural component for the synthesis of more complex compounds, contributing to the advancement of chemical research and development. Its unique properties and reactivity make it a valuable building block in the creation of novel molecules with potential applications in various fields.

InChI:InChI=1/C6H6F3N3/c7-6(8,9)5-1-3(10)4(11)2-12-5/h1-2H,11H2,(H2,10,12)

Upstream product

• 438564-36-4 5-nitro-2-(trifluoromethyl)pyridin-4-amine 
• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 438554-45-1 4-chloro-5-nitro-2-(trifluoromethyl)pyridine 
• 438554-44-0 5-nitro-2-(trifluoromethyl)pyridin-4-ol 

Relevant academic research and scientific papers

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method o

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS

The present invention provides compounds having the formula: (I) wherein A-B together represents one of the following structures; (II), (III), (IV) and n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.

Benzimidazole and pyridylimidazole derivatives

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.